Evidence map›Paper›PMID 27185291›Full record

ArticlemAbs

Development and characterization of synthetic antibodies binding to the cystic fibrosis conductance regulator.

Amandeep K Gakhal, Timothy J Jensen, Zoltan Bozoky, Ariel Roldan, Gergely L Lukacs, Julie Forman-Kay, John R Riordan, Sachdev S Sidhu

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Recent Strategic Advances in CFTR Drug Discovery: An Overview.International journal of molecular sciences · 2020
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Amandeep K Gakhala Donnelly Center for Cellular and Biomolecular Research , University of Toronto , Toronto , Ontario , Canada.
Timothy J Jensenb Department of Biochemistry and Biophysics , Cystic Fibrosis Treatment and Research Center, University of North Carolina , Chapel Hill , NC , USA.
Zoltan Bozokyc Program in Molecular Structure & Function , The Hospital for Sick Children , Toronto , ON , Canada.
Ariel Roldane Department of Physiology and Biochemistry , McGill University , Montreal , QC , Canada.
Gergely L Lukacse Department of Physiology and Biochemistry , McGill University , Montreal , QC , Canada.
Julie Forman-Kayc Program in Molecular Structure & Function , The Hospital for Sick Children , Toronto , ON , Canada.
John R Riordanb Department of Biochemistry and Biophysics , Cystic Fibrosis Treatment and Research Center, University of North Carolina , Chapel Hill , NC , USA.
Sachdev S Sidhua Donnelly Center for Cellular and Biomolecular Research , University of Toronto , Toronto , Ontario , Canada.
University of Toronto · CAMcGill University · CAUniversity of North Carolina at Chapel Hill · US

Funding

Restoration of mutant CFTR stability and functionR01DK051870 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALCH, WILLIAM EDWARD · 1996 to 2020
$8.7M
CIHR MOP-136944NIDDK NIH HHS R01 DK051870
6 · The paper itself

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel in the apical surface of epithelial cells in the airway and gastrointestinal tract, and mutation of CFTR is the underlying cause of cystic fibrosis. However, the precise molecular details of the structure and function of CFTR in native and disease states remains elusive and cystic fibrosis researchers are hindered by a lack of high specificity, high affinity binding reagents for use in structural and biological studies. Here, we describe a panel of synthetic antigen-binding fragments (Fabs) isolated from a phage-displayed library that are specific for intracellular domains of CFTR that include the nucleotide-binding domains (NBD1 and NBD2), the R-region, and the regulatory insertion loop of NBD1. Binding assays performed under conditions that promote the native fold of the protein demonstrated that all Fabs recognized full-length CFTR. However, only the NBD1-specific Fab recognized denatured CFTR by western blot, suggesting a conformational epitope requirement for the other Fabs. Surface plasmon resonance experiments showed that the R-region Fab binds with high affinity to both the phosphorylated and unphosphorylated R-region. In addition, NMR analysis of bound versus unbound R-region revealed a distinct conformational effect upon Fab binding. We further defined residues involved with antibody recognition using an overlapping peptide array. In summary, we describe methodology complementary to previous hybridoma-based efforts to develop antibody reagents to CFTR, and introduce a synthetic antibody panel to aid structural and biological studies.

Indexed as

AntibodiesAntibody AffinityCystic Fibrosis Transmembrane Conductance RegulatorEpitopesHumansImmunoglobulin Fab FragmentsMagnetic Resonance SpectroscopyPeptide LibraryPhosphorylationProtein DomainsProtein EngineeringProtein FoldingSurface Plasmon ResonanceAntibodiesCystic Fibrosis Transmembrane Conductance RegulatorEpitopesImmunoglobulin Fab FragmentsPeptide LibraryCystic fibrosis conductance regulatormembrane proteinphage displayprotein engineeringsynthetic antibody

Identifiers

PMID27185291
PMCPMC4968092
OpenAlexW2402884563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.